| Name | Title | Contact Details |
|---|
Lindsey Management Co., Inc. (LMC) is a leading property management firm located in Fayetteville, Arkansas. Founded in 1985, it has become the largest company in Arkansas specializing in multi-family housing and has expanded its services into neighboring states such as Alabama, Kansas, Mississippi, Missouri, and Oklahoma. LMC provides a wide range of property management services, primarily focusing on multi-family housing. The company manages over 140 apartment communities, totaling more than 32,000 apartments and executive suites. Additionally, LMC oversees numerous golf courses, including five Par 3 courses, five executive courses, thirteen regular courses, and sixteen 18-hole courses across Arkansas and surrounding states. Its services include leasing, maintenance, and customer support for both residential and recreational properties.
The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber business, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 48,000 employees around the world, the company contributes to sustainable society by providing solutions to the worlds challenges through its three business sectors of Material, Homes, and Health Care.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Kerrie Kelly is a multifaceted design studio bringing thoughtful design into everyday life. To work with Kerrie Kelly—whether through residential interiors, corporate partnerships or lifestyle entertainment—is to gain a trusted, industry-savvy partner who bridges the gap between design principles and a life well lived.